Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Consensus Recommendation of “Buy” from Analysts

Aquestive Therapeutics, Inc. (NASDAQ:AQST) has been given a consensus recommendation of “Buy” by the seven research firms that are currently covering the stock, Marketbeat Ratings reports. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $10.67.

Several brokerages have issued reports on AQST. HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Aquestive Therapeutics in a report on Wednesday, April 2nd. Lake Street Capital decreased their price target on shares of Aquestive Therapeutics from $10.00 to $8.00 and set a “buy” rating for the company in a research note on Friday, March 7th. Raymond James set a $7.00 target price on shares of Aquestive Therapeutics in a research report on Friday, March 7th. Finally, Alliance Global Partners reaffirmed a “buy” rating on shares of Aquestive Therapeutics in a research report on Friday, March 7th.

Aquestive Therapeutics Stock Performance

Shares of AQST opened at $2.85 on Friday. The firm has a market cap of $281.78 million, a PE ratio of -6.33 and a beta of 2.59. Aquestive Therapeutics has a 52-week low of $2.20 and a 52-week high of $5.80. The business’s 50 day moving average price is $2.79 and its two-hundred day moving average price is $3.63.

Aquestive Therapeutics (NASDAQ:AQST) last issued its earnings results on Wednesday, March 5th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.05). The company had revenue of $11.87 million for the quarter, compared to analyst estimates of $13.11 million. Research analysts predict that Aquestive Therapeutics will post -0.46 EPS for the current fiscal year.

Hedge Funds Weigh In On Aquestive Therapeutics

Several hedge funds have recently modified their holdings of the company. Price T Rowe Associates Inc. MD increased its position in shares of Aquestive Therapeutics by 16.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 27,669 shares of the company’s stock valued at $99,000 after purchasing an additional 3,821 shares during the last quarter. MetLife Investment Management LLC boosted its holdings in shares of Aquestive Therapeutics by 11.4% in the 4th quarter. MetLife Investment Management LLC now owns 40,221 shares of the company’s stock worth $143,000 after buying an additional 4,125 shares during the last quarter. Bank of Montreal Can grew its position in Aquestive Therapeutics by 10.1% during the fourth quarter. Bank of Montreal Can now owns 54,300 shares of the company’s stock valued at $193,000 after buying an additional 4,999 shares during the period. Charles Schwab Investment Management Inc. increased its holdings in Aquestive Therapeutics by 3.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 210,669 shares of the company’s stock worth $750,000 after buying an additional 7,129 shares during the last quarter. Finally, SG Americas Securities LLC raised its position in Aquestive Therapeutics by 28.7% in the fourth quarter. SG Americas Securities LLC now owns 32,966 shares of the company’s stock worth $117,000 after acquiring an additional 7,347 shares during the period. Institutional investors own 32.45% of the company’s stock.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.